MCID: GLC003
MIFTS: 54

Glucose Intolerance

Categories: Metabolic diseases

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 12 29 54 6 43 15
Impaired Glucose Tolerance 71
Malabsorption of Glucose 12
Glucose: Malabsorption 12
Glucose: Intolerance 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10603
MeSH 43 D018149
NCIt 49 C34646
SNOMED-CT 67 267426009
ICD10 32 R73.03
UMLS 71 C0271650

Summaries for Glucose Intolerance

MalaCards based summary : Glucose Intolerance, also known as impaired glucose tolerance, is related to lipodystrophy, familial partial, type 2 and abdominal obesity-metabolic syndrome 1. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA-Leu (UUA/G) 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Amiloride and Rosiglitazone have been mentioned in the context of this disorder. Affiliated tissues include liver, ovary and testes, and related phenotypes are adipose tissue and endocrine/exocrine gland

Wikipedia : 74 Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels... more...

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 32.7 SLC2A4 LEP INS ADIPOQ
2 abdominal obesity-metabolic syndrome 1 31.8 SLC2A4 RETN LEPR LEP INSR INS
3 fatty liver disease, nonalcoholic 1 31.7 RETN LEP INS GPT ADIPOQ
4 lipid metabolism disorder 31.3 SHBG RETN RBP4 LEP IRS1 INSR
5 uremia 31.3 RETN LEP INS GH1
6 atherosclerosis susceptibility 31.2 RETN LEP INS ADIPOQ
7 fatty liver disease 31.2 RETN RBP4 LEPR LEP IRS1 INSR
8 liver disease 31.1 RETN LEPR LEP IRS1 INSR INS
9 kidney disease 31.1 RETN RBP4 LEP INS GCG DPP4
10 vascular disease 30.9 RETN LEP INS IGFBP1 IGF1 ADIPOQ
11 liver cirrhosis 30.9 SLC2A4 RETN RBP4 LEPR LEP GPT
12 polycystic ovary syndrome 30.9 SHBG RETN LEP IRS1 INSR INS
13 hypoglycemia 30.9 INSR INS IGFBP1 IGF1 GHRL GH1
14 hyperglycemia 30.9 SLC2A4 RETN LEP IRS1 INSR INS
15 pre-eclampsia 30.9 LEPR LEP INS IGFBP1 IGF1 GPT
16 hyperproinsulinemia 30.9 SHBG INS IGFBP1
17 acute insulin response 30.9 INS GCG
18 fetal macrosomia 30.9 LEP INSR INS IGF1
19 genetic obesity 30.8 LEPR LEP IGF1
20 arteriosclerosis 30.8 SHBG INS GPT GHRL ADIPOQ
21 familial hyperlipidemia 30.8 LEP INS GPT ADRB3 ADIPOQ
22 gestational diabetes 30.8 SLC2A4 SHBG RETN RBP4 LEPR LEP
23 thyroid gland disease 30.7 SHBG LEP INS IGF1 GPT
24 hyperandrogenism 30.7 SHBG INSR INS IGFBP1 IGF1 GH1
25 hyperthyroidism 30.7 SHBG RETN LEP INS IGF1 GPT
26 sleep apnea 30.6 RETN LEPR LEP INS IGF1 GPT
27 cerebrovascular disease 30.6 RETN LEP INS ADIPOQ
28 insulin-like growth factor i 30.6 SHBG LEP IRS1 INSR INS IGFBP1
29 non-alcoholic steatohepatitis 30.6 SLC2A4 LEPR IRS1 INS IGF1 GPT
30 acromegaly 30.6 SHBG LEPR LEP INS IGFBP1 IGF1
31 hyperinsulinism 30.5 SLC2A4 SHBG RETN LEPR LEP IRS1
32 non-alcoholic fatty liver disease 30.5 SLC2A4 RETN RBP4 LEPR LEP IRS1
33 anovulation 30.5 SHBG LEP INS IGFBP1 IGF1 GHRL
34 prediabetes syndrome 30.5 SLC2A4 LEP IRS1 INS IGF1 GPT
35 diabetes mellitus, ketosis-prone 30.5 INS GCG DPP4
36 acanthosis nigricans 30.5 SLC2A4 SHBG LEP INSR INS IGF1
37 hypothyroidism 30.5 SHBG RETN LEP INS IGF1 GPT
38 hyperinsulinemic hypoglycemia 30.5 INSR INS GCK GCG
39 hyperprolactinemia 30.4 SHBG INS IGF1 GH1
40 sleep disorder 30.4 LEP INS IGF1 GHRL ADIPOQ
41 amenorrhea 30.4 SHBG LEP INS IGF1 GHRL
42 peripheral nervous system disease 30.4 LEP INS IGF1 GPT GCG DPP4
43 apnea, obstructive sleep 30.3 RETN LEP INS IGF1 GPT GHRL
44 hypopituitarism 30.3 SHBG LEP INS IGF1 GH1
45 conn's syndrome 30.3 LEP IGF1 GHRL GH1 ADIPOQ
46 myocardial infarction 30.3 SHBG RETN LEP INS IGFBP1 IGF1
47 goiter 30.3 SHBG INS IGF1
48 hypogonadism 30.3 SHBG LEPR LEP INS IGF1
49 pancreas disease 30.2 LEP INS IGF1 GCG DPP4
50 maturity-onset diabetes of the young 30.2 GCG DPP4 LEP IRS1 INS GCK

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.2 ADIPOQ ADRB3 GHRL IGF1 INS INSR
2 endocrine/exocrine gland MP:0005379 10.18 ADIPOQ ADRB3 DPP4 GCK GHRL IGF1
3 cardiovascular system MP:0005385 10.17 ADIPOQ DPP4 GCK IGF1 INS INSR
4 homeostasis/metabolism MP:0005376 10.17 ADIPOQ ADRB3 DPP4 GCK GHRL IGF1
5 cellular MP:0005384 10.14 ADIPOQ GCK IGF1 IGFBP1 INS INSR
6 immune system MP:0005387 10 ADIPOQ DPP4 IGF1 IGFBP1 INS INSR
7 liver/biliary system MP:0005370 9.85 ADIPOQ GCK IGFBP1 INS INSR IRS1
8 muscle MP:0005369 9.61 ADIPOQ IGF1 INS INSR IRS1 LEP
9 renal/urinary system MP:0005367 9.23 ADIPOQ GCK IGF1 INS INSR LEP

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 540)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
2
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
3
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
4
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
5
Glyburide Approved Phase 4 10238-21-8 3488
6
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
7
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
8
Linagliptin Approved Phase 4 668270-12-0 10096344
9
Trandolapril Approved Phase 4 87679-37-6 5484727
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Insulin glargine Approved Phase 4 160337-95-1
12
Clozapine Approved Phase 4 5786-21-0 2818
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
16
Iloperidone Approved Phase 4 133454-47-4 71360
17
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
18
Hydroxychloroquine Approved Phase 4 118-42-3 3652
19
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
20
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
21
Atorvastatin Approved Phase 4 134523-00-5 60823
22
Verapamil Approved Phase 4 52-53-9 2520
23
Chlorthalidone Approved Phase 4 77-36-1 2732
24
Budesonide Approved Phase 4 51333-22-3 63006 5281004
25
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
26
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
27
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
28
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
29
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
30
Dulaglutide Approved, Investigational Phase 4 923950-08-7
31
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
32
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
33
Glucagon Approved Phase 4 16941-32-5
34
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
35
Methyltestosterone Approved Phase 4 58-18-4 6010
36
Testosterone enanthate Approved Phase 4 315-37-7 9416
37
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
38
Saxagliptin Approved Phase 4 361442-04-8 11243969
39
Sodium citrate Approved, Investigational Phase 4 68-04-2
40
Losartan Approved Phase 4 114798-26-4 3961
41
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
42
Enalaprilat Approved Phase 4 76420-72-9 6917719
43
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
44
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
45
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
46
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
47
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
48 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
49
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
50
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013

Interventional clinical trials:

(show top 50) (show all 1083)
# Name Status NCT ID Phase Drugs
1 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
2 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
3 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
4 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
5 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
6 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
7 The Impacts of Vitamin D Supplementation on Glucose Metabolism in Chinese Women With Vitamin D Deficiency and Former Gestational Diabetes Mellitus:A Randomised Control Trial Unknown status NCT03138616 Phase 4 vitamin D
8 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
9 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
10 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
11 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
12 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
13 Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance Completed NCT00319189 Phase 4 Nateglinide
14 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
15 Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons? Completed NCT01219231 Phase 4
16 The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance Completed NCT00546728 Phase 4 Exenatide;Metformin
17 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
18 A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt) Completed NCT00241072 Phase 4 valsartan
19 Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function Completed NCT01588418 Phase 4 Exenatide;Placebo
20 The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08 Completed NCT00740363 Phase 4 sitagliptin;placebo
21 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
22 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
23 Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
24 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
25 A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
26 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
27 Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol with concomitant losartan or lisinopril;HCTZ with concomitant losartan or lisinopril;Placebo with concomitant losartan or lisinopril
28 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
29 A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill
30 Metabolic Effects of Antihypertensive Drugs Completed NCT00887510 Phase 4 Hydrochlorothiazide;Trandolapril
31 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
32 The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus Completed NCT00456885 Phase 4 exenatide;Placebo
33 Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
34 Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
35 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
36 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4 Exenatide
37 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS Completed NCT01497132 Phase 4 Vitamin D3;Placebo
38 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
39 Quantitative Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking the Antipsychotic Medications Fanapt (Iloperidone) or Zyprexa (Olanzapine) or Placebo Completed NCT01920802 Phase 4 olanzapine;iloperidone;Placebo
40 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
41 Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial Completed NCT00847080 Phase 4 Sitagliptin phosphate;Placebo
42 Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
43 One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements Completed NCT00483769 Phase 4 Glargine
44 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
45 Effects of Cyclosporine A on Pancreatic Insulin Secretion Completed NCT00139035 Phase 4 cyclosporine A
46 Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients Completed NCT00138970 Phase 4 Zenapax®, CellCept® and prednisolone;Sandimmun Neoral®, CellCept® and prednisolone
47 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
48 Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Completed NCT01475513 Phase 4 Ortho Cyclen®
49 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
50 Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial Completed NCT01765946 Phase 4 Metformin;placebo

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 71 / NDF-RT 50 :


glucomannan

Cochrane evidence based reviews: glucose intolerance

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 29

Anatomical Context for Glucose Intolerance

MalaCards organs/tissues related to Glucose Intolerance:

40
Liver, Ovary, Testes, Heart, Skeletal Muscle, Endothelial, Adipocyte

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 10359)
# Title Authors PMID Year
1
Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. 54 61
20332348 2010
2
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. 61 54
20469868 2010
3
Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. 61 54
19914667 2010
4
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. 54 61
20147524 2010
5
Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage? 54 61
19815054 2010
6
Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). 61 54
20105040 2010
7
Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. 54 61
19804472 2010
8
Retinol-binding protein 4 levels in obese children and adolescents with glucose intolerance. 61 54
20389103 2010
9
Adiponectin in insulin resistance: lessons from translational research. 61 54
19906806 2010
10
Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. 61 54
19697961 2009
11
Acromegaly pathogenesis and treatment. 61 54
19884662 2009
12
The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. 54 61
19688613 2009
13
The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. 54 61
19576817 2009
14
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. 54 61
19542241 2009
15
Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. 54 61
19351735 2009
16
Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss. 54 61
19627193 2009
17
Pre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity. 54 61
18793347 2009
18
Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. 54 61
19003725 2009
19
Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes. 61 54
19260948 2009
20
Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. 54 61
18624998 2009
21
Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. 61 54
18847384 2009
22
A cross-sectional study for glucose intolerance of myotonic dystrophy. 54 61
18834994 2009
23
Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. 54 61
18812482 2008
24
[Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients]. 54 61
19140314 2008
25
Ketogenic diet-fed rats have increased fat mass and phosphoenolpyruvate carboxykinase activity. 54 61
18655006 2008
26
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. 61 54
18803955 2008
27
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. 54 61
18854155 2008
28
Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. 54 61
18647805 2008
29
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. 54 61
18633104 2008
30
Associations between sex hormone binding globulin and metabolic syndrome parameters in premenopausal obese women. 54 61
19008614 2008
31
A cross-sectional study of the association between persistent organic pollutants and glucose intolerance among Greenland Inuit. 61 54
18560802 2008
32
High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. 61 54
18492757 2008
33
Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. 61 54
18388893 2008
34
Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. 61 54
18334585 2008
35
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. 54 61
17706206 2008
36
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. 61 54
17904401 2008
37
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 61 54
18235053 2008
38
Adiponectin and its role in cardiovascular diseases. 61 54
18336252 2008
39
Insulin and its role in chronic kidney disease. 61 54
17929061 2008
40
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. 54 61
17944883 2008
41
How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. 54 61
17387006 2007
42
Suppressive effects of diacylglycerol oil on postprandial hyperlipidemia in insulin resistance and glucose intolerance. 61 54
17125771 2007
43
Glucocorticoids and cardiovascular disease. 54 61
17984234 2007
44
Muscle GLUT4 in cirrhosis. 61 54
17448565 2007
45
Fetal determinants of type 2 diabetes. 61 54
17691930 2007
46
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. 61 54
16814296 2007
47
Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance. 61 54
17512320 2007
48
[Effect of progressive insulin resistance on the correlation of glucose metabolism and bone status]. 54 61
17561482 2007
49
Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. 61 54
17418606 2007
50
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. 54 61
17403409 2007

Variations for Glucose Intolerance

ClinVar genetic disease variations for Glucose Intolerance:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-TL1 NC_012920.1:m.3243A>GSNV Pathogenic 9589 rs199474657 MT:3243-3243 MT:3243-3243

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Pathways for Glucose Intolerance

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 LEPR LEP IRS1 INSR INS GCG
2
Show member pathways
12.9 SLC2A4 IRS1 INSR INS IGF1 GH1
3
Show member pathways
12.68 SLC2A4 RETN RBP4 LEP IRS1 INSR
4 12.51 SLC2A4 IRS1 INSR INS IGFBP1 GCG
5
Show member pathways
12.45 LEPR LEP IRS1 INS GH1 GCK
6
Show member pathways
12.44 SLC2A4 IRS1 INSR INS
7
Show member pathways
12.42 IRS1 INSR INS IGF1
8
Show member pathways
12.28 IRS1 INSR IGF1 ADRB3
9
Show member pathways
12.22 SLC2A4 LEPR LEP IRS1 INSR INS
10
Show member pathways
12.21 SLC2A4 LEP IRS1 INSR INS
11
Show member pathways
12.13 IRS1 INSR INS IGF1 ADIPOQ
12
Show member pathways
12.07 SLC2A4 IRS1 INSR INS IGF1
13
Show member pathways
12.06 LEP INS IGF1 GHRL GH1 GCG
14
Show member pathways
11.95 SLC2A4 IRS1 INSR INS
15 11.87 SLC2A4 LEP INS IGF1 ADIPOQ
16
Show member pathways
11.78 SLC2A4 IRS1 INSR INS GCK ADIPOQ
17 11.69 SLC2A4 LEPR LEP IRS1 ADIPOQ
18 11.64 IRS1 INSR INS
19 11.63 LEP IGFBP1 GCK
20 11.62 IRS1 INSR INS ADRB3
21
Show member pathways
11.56 LEP GCG DPP4
22 11.56 SLC2A4 LEPR LEP IRS1
23 11.52 INSR INS IGF1
24 11.47 LEPR LEP IRS1 INSR INS
25 11.45 INS IGFBP1 GCK
26 11.43 IRS1 INSR INS
27 11.38 IRS1 INSR INS IGF1
28 11.35 SLC2A4 RETN LEP IRS1 INS IGF1
29 11.26 SLC2A4 INSR INS
30 11.03 LEPR LEP INS GHRL
31
Show member pathways
10.98 SLC2A4 IRS1 INSR
32 10.97 SLC2A4 INS GPT
33 10.7 SLC2A4 LEP IRS1 INSR ADIPOQ

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 RETN RBP4 LEP INS IGFBP1 IGF1
2 endoplasmic reticulum lumen GO:0005788 9.56 INS IGFBP1 GHRL GCG
3 extracellular region GO:0005576 9.44 SHBG RETN RBP4 LEPR LEP INS
4 insulin receptor complex GO:0005899 9.16 IRS1 INSR

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 RETN LEP IRS1 INS IGFBP1 IGF1
2 positive regulation of cell proliferation GO:0008284 10.08 LEP IRS1 INSR INS IGF1 DPP4
3 positive regulation of protein phosphorylation GO:0001934 9.95 LEPR LEP INSR ADIPOQ
4 carbohydrate metabolic process GO:0005975 9.95 SLC2A4 INSR INS GCK ADRB3
5 positive regulation of protein kinase B signaling GO:0051897 9.93 LEP IRS1 INSR INS
6 response to ethanol GO:0045471 9.89 SLC2A4 RBP4 LEP ADIPOQ
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 IGF1 GH1 ADIPOQ
8 positive regulation of MAPK cascade GO:0043410 9.85 LEP INSR INS IGF1 ADRB3
9 response to insulin GO:0032868 9.84 RETN LEP IRS1
10 insulin receptor signaling pathway GO:0008286 9.84 IRS1 INSR INS IGFBP1
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 LEP IGF1 GH1
12 regulation of insulin secretion GO:0050796 9.83 LEP GCK GCG DPP4
13 positive regulation of cold-induced thermogenesis GO:0120162 9.83 LEPR LEP GHRL ADRB3 ADIPOQ
14 response to nutrient levels GO:0031667 9.81 LEP GHRL GH1 ADIPOQ
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 LEP INSR INS IGF1 GH1
16 positive regulation of insulin secretion GO:0032024 9.79 RBP4 GHRL GCK
17 activation of protein kinase B activity GO:0032148 9.77 INSR INS IGF1
18 glucose metabolic process GO:0006006 9.77 LEP INS GHRL GCK ADIPOQ
19 positive regulation of mitotic nuclear division GO:0045840 9.76 INSR INS IGF1
20 positive regulation of glycolytic process GO:0045821 9.75 INSR INS IGF1
21 positive regulation of insulin receptor signaling pathway GO:0046628 9.74 LEP IRS1 INS
22 insulin-like growth factor receptor signaling pathway GO:0048009 9.68 IRS1 IGF1
23 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.68 IGF1 GH1
24 positive regulation of growth GO:0045927 9.68 GHRL GH1
25 adult feeding behavior GO:0008343 9.67 LEP GHRL
26 leptin-mediated signaling pathway GO:0033210 9.67 LEPR LEP
27 sexual reproduction GO:0019953 9.67 LEPR LEP
28 energy reserve metabolic process GO:0006112 9.67 LEPR LEP ADRB3
29 neuron projection maintenance GO:1990535 9.66 INSR INS
30 positive regulation of respiratory burst GO:0060267 9.65 INSR INS
31 cellular response to leptin stimulus GO:0044320 9.65 LEPR LEP GCK
32 positive regulation of glucose import GO:0046326 9.65 IRS1 INSR INS IGF1 ADIPOQ
33 negative regulation of feeding behavior GO:2000252 9.64 RETN INS
34 regulation of bone remodeling GO:0046850 9.64 LEPR LEP
35 bone mineralization involved in bone maturation GO:0035630 9.63 LEP IGF1
36 positive regulation of developmental growth GO:0048639 9.62 LEP INSR
37 negative regulation of gluconeogenesis GO:0045721 9.62 LEPR INS GCK ADIPOQ
38 bone growth GO:0098868 9.61 LEPR LEP
39 positive regulation of glycogen biosynthetic process GO:0045725 9.55 IRS1 INSR INS IGF1 GCK
40 cellular response to insulin stimulus GO:0032869 9.5 SLC2A4 LEP IRS1 INSR GPT GCK
41 glucose homeostasis GO:0042593 9.28 SLC2A4 RBP4 LEPR LEP IRS1 INSR

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 LEP IGFBP1 GCG DPP4 ADIPOQ
2 insulin-like growth factor I binding GO:0031994 9.37 INSR IGFBP1
3 insulin receptor binding GO:0005158 9.33 IRS1 INS IGF1
4 insulin-like growth factor II binding GO:0031995 9.32 INSR IGFBP1
5 insulin-like growth factor receptor binding GO:0005159 9.26 IRS1 INSR INS IGF1
6 hormone activity GO:0005179 9.23 RETN LEP INS IGF1 GHRL GH1

Sources for Glucose Intolerance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....